Bone Density Interpretation and Relevance in Caucasian Children Aged 9–17 Years of Age: Insights From a Population-Based Fracture Study

2006 ◽  
Vol 9 (2) ◽  
pp. 202-209 ◽  
Author(s):  
Graeme Jones ◽  
Deqiong Ma ◽  
Fergus Cameron
Keyword(s):  
Bone Density ◽  
Population Based ◽  
Fracture Study

scholarly journals Population-based geographic variations in dxa bone density in Europe: The evos study

1997 ◽  
Vol 7 (3) ◽  
pp. 175-189 ◽  
Author(s):  
M. Lunt ◽  
D. Felsenberg ◽  
J. Adams ◽  
L. Benevolenskaya ◽  
J. Cannata ◽  
...  
Keyword(s):  
Bone Density ◽  
Population Based ◽  
Geographic Variations

scholarly journals Serum 25(OH)D3 vitamin status of elderly Finnish women is suboptimal even after summer sunshine but is not associated with bone density or turnover

2010 ◽  
Vol 162 (1) ◽  
pp. 183-189 ◽  
Author(s):  
Tuula Pekkarinen ◽  
Ursula Turpeinen ◽  
Esa Hämäläinen ◽  
Eliisa Löyttyniemi ◽  
Henrik Alfthan ◽  
...  
Keyword(s):  
Vitamin D ◽  
Bone Density ◽  
Bone Turnover ◽  
Population Based ◽  
Type I ◽  
Vitamin D Status ◽  
Mineral Density ◽  
Type I Procollagen ◽  
Before And After ◽  
Before And After Summer

ObjectiveConcentrations of 50 and 75 nmol/l are proposed as serum 25-hydroxyvitamin D (25(OH)D) target for older people from the view of bone health. We evaluated vitamin D status of elderly Finnish women in light of these definitions, its relationship to bone mineral density (BMD) and turnover, and improvement by summer sunshine.DesignPopulation-based study.MethodsA total of 1604 ambulatory women aged 62–79 years were studied; 66% used vitamin D supplements. Serum 25(OH)D3was measured with HPLC before and after summer, and heel BMD in spring. In subgroups, serum parathyroid hormone (PTH) and type I procollagen aminoterminal propeptide (PINP) were analyzed.ResultsIn spring, 60.3% of the women had 25(OH)D3≤50 nmol/l, and the target of 75 nmol/l was reached by 9.1%. For supplement users, the respective numbers were 52.1 and 11.9%. Serum 25(OH)D3did not determine BMD or bone turnover measured by serum PINP. Summer sunshine increased serum 25(OH)D3by 17.4% (P<0.0001), but in autumn 84% of the subjects remained under the target of 75 nmol/l. In supplement users, PTH remained stable but decreased in others during summer (P=0.025).ConclusionsVitamin D status of elderly Finnish women is suboptimal if 25(OH)D3levels of 50 or 75 nmol/l are used as a threshold. It is moderately increased by supplement intake and summer sunshine. However, 25(OH)D3concentrations did not influence bone density in terms of serum PINP and bone turnover rate.

Physical activity in adolescence and bone density in periand postmenopausal women: A population-based study

Bone ◽  
1997 ◽  
Vol 21 (4) ◽  
pp. 363-367 ◽  
Author(s):  
E. Puntila ◽  
H. Kröger ◽  
T. Lakka ◽  
R. Honkanen ◽  
M. Tuppurainen
Keyword(s):  
Physical Activity ◽  
Bone Density ◽  
Postmenopausal Women ◽  
Population Based ◽  
Population Based Study

ANABOLIC THERAPY AND OPTIMAL TREATMENT SEQUENCES FOR PATIENTS WITH OSTEOPOROSIS AT HIGH RISK FOR FRACTURE

2020 ◽  
Vol 26 (7) ◽  
pp. 777-786 ◽  
Author(s):  
Felicia Cosman
Keyword(s):  
Bone Mineral Density ◽  
High Risk ◽  
Bone Density ◽  
Fracture Risk ◽  
Postmenopausal Women ◽  
Bone Mineral ◽  
Mineral Density ◽  
Anabolic Agents ◽  
Anabolic Therapy ◽  
Fracture Study

Objective: Provide an update regarding anabolic medications for osteoporosis, which are often considered to be the last resort for patients with osteoporosis, after multiple fractures have already occurred and other medications have already been administered. Methods: Literature review and discussion. Results: Recent pivotal trial data for anabolic agents and randomized trials comparing anabolic and antiresorptive medications suggest that three anabolic agents (teriparatide, abaloparatide, and romosozumab) reduce nonvertebral and vertebral fractures faster and to a greater extent than potent antiresorptive treatments. Furthermore, bone density accrual is maximized when patients are given anabolic agents first, followed by potent antiresorptive therapy. Since total hip bone density during or after osteoporosis treatment has emerged as an excellent surrogate for future fracture risk, attaining a greater hip bone mineral density is a treatment goal for high-risk osteoporosis patients. Conclusion: This review defines the highest-risk patients and summarizes the rationale for the evolving role of anabolic therapy in the management of postmenopausal women at high risk for fracture. Abbreviations: ACTIVE = Abaloparatide Comparator Trial in Vertebral Endpoints; ARCH = Active Controlled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk; BMD = bone mineral density; FRAME = Fracture Study in Postmenopausal Women with Osteoporosis; FRAX = Fracture Risk Assessment Tool; PTH = parathyroid hormone; TBS = trabecular bone score

Sign in / Sign up

Export Citation Format

Share Document